We have located links that may give you full text access.
Forestalling BRAF-Inhibitor Resistance in a Shocking Way.
Clinical Cancer Research 2018 July 7
Targeting BRAF in BRAF -mutant melanoma is highly effective, but most patients develop resistance. HSP90 has been implicated and identified as a therapeutic target. Ultimately, early-stage clinical investigation will be necessary to provide proof of principle of this approach and if appropriate randomized trials to confirm promising findings. Clin Cancer Res; 1-3. ©2018 AACR.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app